Trial record 15 of 225 for:
Open Studies | "Hyperglycemia"
Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes
Verified December 2013 by Rabin Medical Center
Information provided by (Responsible Party):
Amit Tirosh, Rabin Medical Center
First received: December 15, 2013
Last updated: December 22, 2013
Last verified: December 2013
Glucocorticoids therapy exposes the patient to an increased risk for diabetes morbidity. However, there is no proven preventive therapy. GLP-1-RA has shown to improve glucose metabolism in healthy volunteers treated with glucocorticoids. We assume that GLP-1-RA will improve glucose metabolism in patients with high risk for diabetes morbidity, treated with glucocorticoids.
Glucocorticoid Induced Hyperglycemia
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Primary Outcome Measures:
- Glucose levels 2 hours after 75 gr OGTT [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||January 2015 (Final data collection date for primary outcome measure)
Placebo Comparator: Placebo
Active Comparator: Intervention
Liraglutide, tapered from 0.6 mg/day to 1.8 mg/day.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Planned treatment with T. Prednisone in dosage >0.5 mg/kg for two weeks or more.
- Age >18 years
- Body mass index >27 kg/m2 OR 1st degree relative with type 2 diabetes mellitus OR hypertension OR hyperlipidemia OR gestational diabetes in the past OR diagnosis of polycystic ovary syndrome.
- Glycosylated hemoglobin A1c >6.5%
- Diagnosis of diabetes mellitus or treatment with anti-glycemic drug
- Pancreatitis (acute or chronic) in the past
- Active malignancy
- Medullary thyroid carcinoma or multiple endocrine neoplasm type 2 of the patient or of 1st degree relative
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02016846
|Rabin Medical Center, Beilinson Campus
|Petah Tiqva, Israel |
|Contact: Amit Tirosh, MD email@example.com |
Rabin Medical Center
No publications provided
||Amit Tirosh, Dr, Rabin Medical Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 15, 2013
||December 22, 2013
||Israel: Clalit Health Services
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 11, 2014
Glucose Metabolism Disorders
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs